Inactief instrument

Andere talen PHOX BIOT26 Nasdaq

Aandelen

PBAXU

US71902K2042

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes	30/04
PHOX BIOT26 : CERo Therapeutics Investor Presentation	25/04
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Top Premarket Decliners	11/03
Top Premarket Gainers	08/03
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients	07/03
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients	07/03
CERo Therapeutics Holdings, Inc. announced that it expects to receive $25 million in funding from Arena Business Solutions Global SPC II, Ltd.	23/02
Top Premarket Decliners	20/02
Phoenix Biotech Acquisition Completes Merger With CERo Therapeutics	15/02
Phoenix Biotech Acquisition Corp. Appoints Brian Atwood as Chief Executive Officer	15/02
Phoenix Biotech Acquisition Corp. Announces Executive and Board Changes	15/02
Phoenix Biotech Acquisition Corp. Appoints Charles Carter as Chief Financial Officer	15/02
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination	14/02
Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index	14/02
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	14/02
CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding	14/02
Phoenix Biotech Acquisition Corp. Sinks 15% in Premarket Activity After Plunging 42% in Wednesday's Regular Trading	08/02
Phoenix Biotech Acquisition Corp. announced that it expects to receive $2 million in funding from Keystone Capital Partners LLC	05/02
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen PHOX BIOT26 Nasdaq

Aandelen

PBAXU

US71902K2042

Andere talen

Filters